New drug aims to protect kidneys in IgA nephropathy patients

NCT ID NCT07582133

Recruiting now Disease control Sponsor: Chengdu Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 23, 2026 · Updated 4 times

Summary

This study tests the long-term safety of HRS-5965 capsules in 380 adults with primary IgA nephropathy, a kidney disease. Participants will take the drug and be monitored for side effects, as well as changes in urine protein and kidney function. The goal is to see if HRS-5965 can safely reduce kidney damage over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-5965 capsules
What this could lead to: If successful, this could provide a new treatment option to slow kidney damage and delay the need for dialysis or transplant in people with IgA nephropathy.
What could go wrong: This is an early-phase, open-label trial with no placebo group, so results may not confirm effectiveness. Long-term safety is still unknown, and the drug may cause side effects or fail to outperform existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IGA NEPHROPATHY

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.